The goal of this clinical trial is to develop an innovative web-based dance movement therapy (DMT) training platform and assess short-term outcomes before and after its implementation in women with breast cancer Is the DMT training platform comprehensibility and acceptability among patients? Is the DMT training platform acceptability, usability, and feasibility among healthcare providers? Does the DMT training platform have effects on alexithymia and frailty among patients? Researchers will compare experimental to a control (a a conventional care program) to see if DMT training platform works to treat severe asthma. Participants will: receive an orientation on the web-based DMT program before chemotherapy, along with a single face-to-face traditional education session on physical activity . complete training sessions three times per week, with each session lasting at least 70 min.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
67
Patients in the experimental group received an orientation on the web-based DMT program before chemotherapy, along with a single face-to-face traditional education session on physical activity. Participants were encouraged to complete training sessions three times per week, with each session lasting at least 70 min. Each DMT training session was divided into four components: (1) Proprioception; (2)Warm-up and stretching techniques; (3) Main part; (4) Relaxation.
National Yang Ming Chiao Tung University
Taipei, Taiwan
Alexithymia
Alexithymia was assessed using the Chinese version of the Toronto Alexithymia Scale (TAS), a self-reported outcome measure \[30-31\]. The TAS consists of 20 items covering three key domains: difficulty in identifying and discriminating emotional cues, difficulty in verbally expressing emotions and feelings, and externally oriented thinking. Each item was rated on a 5-point Likert scale, ranging from 1 to 5, resulting in a total score range of 20 to 100, with higher scores indicating greater alexithymia.
Time frame: one year (2024/08/01-2025/07/31)
Frailty
A breast cancer comprehensive frailty scale (BCCFS) was developed to assess frailty across three domains: deterioration in body function and mobility, negative emotional states, and cognitive impairment. The BCCFS comprises 16 items and has demonstrated strong psychometric properties, with a Cronbach's alpha of 0.91, indicating excellent internal consistency, and a test-retest reliability coefficient of 0.60 \[32\]. The validity and reliability of the BCCFS have been well established. Responses to each item were recorded on a five-point Likert scale, with higher scores indicating greater perceived frailty.
Time frame: one year ( 2024/08/01-2025/07/31).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.